|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/26 | |
| A61P 11/00 | |||
| A61P 25/00 |
| (11) | Number of the document | 2496249 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10828932.3 |
| Date of filing the European patent application | 2010-10-28 | |
| (97) | Date of publication of the European application | 2012-09-12 |
| (45) | Date of publication and mention of the grant of the patent | 2016-03-09 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2010/054553 |
| Date | 2010-10-28 |
| (87) | Number | WO 2011/056713 |
| Date | 2011-05-12 |
| (30) | Number | Date | Country code |
| 257603 P | 2009-11-03 | US |
| (72) |
VAN CAUTER, Eve, US
|
| (73) |
Eli Lilly and Company,
Lilly Corporate Center, Indianapolis, IN 46285,
US
Amylin Pharmaceuticals, LLC, 1800 Concord Pike, Wilmington, DE 19850, US |
| (54) | GLP-1 RECEPTOR AGONIST FOR USE IN TREATING OBSTRUCTIVE SLEEP APNEA |
| GLP-1 RECEPTOR AGONIST FOR USE IN TREATING OBSTRUCTIVE SLEEP APNEA |